vTv Therapeutics (VTVT) Competitors $19.74 +0.93 (+4.91%) As of 04/17/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTVT vs. CKPT, YMAB, NVCT, OCGN, LFCR, GOSS, CRGX, PLX, HUMA, and ZYBTShould you be buying vTv Therapeutics stock or one of its competitors? The main competitors of vTv Therapeutics include Checkpoint Therapeutics (CKPT), Y-mAbs Therapeutics (YMAB), Nuvectis Pharma (NVCT), Ocugen (OCGN), Lifecore Biomedical (LFCR), Gossamer Bio (GOSS), CARGO Therapeutics (CRGX), Protalix BioTherapeutics (PLX), Humacyte (HUMA), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry. vTv Therapeutics vs. Checkpoint Therapeutics Y-mAbs Therapeutics Nuvectis Pharma Ocugen Lifecore Biomedical Gossamer Bio CARGO Therapeutics Protalix BioTherapeutics Humacyte Zhengye Biotechnology Checkpoint Therapeutics (NASDAQ:CKPT) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership, analyst recommendations and community ranking. Do analysts prefer CKPT or VTVT? Checkpoint Therapeutics presently has a consensus price target of $4.33, suggesting a potential upside of 7.26%. vTv Therapeutics has a consensus price target of $35.50, suggesting a potential upside of 80.20%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe vTv Therapeutics is more favorable than Checkpoint Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Checkpoint Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33vTv Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CKPT or VTVT more profitable? Checkpoint Therapeutics' return on equity of 0.00% beat vTv Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Checkpoint TherapeuticsN/A N/A -659.07% vTv Therapeutics N/A -184.64%-47.29% Does the media prefer CKPT or VTVT? In the previous week, vTv Therapeutics had 6 more articles in the media than Checkpoint Therapeutics. MarketBeat recorded 6 mentions for vTv Therapeutics and 0 mentions for Checkpoint Therapeutics. vTv Therapeutics' average media sentiment score of 0.67 beat Checkpoint Therapeutics' score of 0.00 indicating that vTv Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Checkpoint Therapeutics Neutral vTv Therapeutics Positive Which has better valuation & earnings, CKPT or VTVT? vTv Therapeutics has higher revenue and earnings than Checkpoint Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Checkpoint Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCheckpoint Therapeutics$41K8,253.82-$51.85M-$1.43-2.83vTv Therapeutics$1.02M61.79-$20.25M-$3.41-5.78 Do institutionals & insiders hold more shares of CKPT or VTVT? 22.0% of Checkpoint Therapeutics shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 2.1% of Checkpoint Therapeutics shares are held by insiders. Comparatively, 1.3% of vTv Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor CKPT or VTVT? vTv Therapeutics received 171 more outperform votes than Checkpoint Therapeutics when rated by MarketBeat users. However, 67.16% of users gave Checkpoint Therapeutics an outperform vote while only 57.12% of users gave vTv Therapeutics an outperform vote. CompanyUnderperformOutperformCheckpoint TherapeuticsOutperform Votes18267.16% Underperform Votes8932.84% vTv TherapeuticsOutperform Votes35357.12% Underperform Votes26542.88% Which has more risk & volatility, CKPT or VTVT? Checkpoint Therapeutics has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, vTv Therapeutics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. SummaryvTv Therapeutics beats Checkpoint Therapeutics on 9 of the 17 factors compared between the two stocks. Get vTv Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTVT vs. The Competition Export to ExcelMetricvTv TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.84M$6.45B$5.30B$7.35BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-4.356.8921.8017.80Price / Sales61.79231.03379.9697.74Price / CashN/A65.6738.2634.64Price / Book-2.135.936.443.98Net Income-$20.25M$142.99M$3.21B$247.73M7 Day Performance4.95%4.43%2.88%1.81%1 Month Performance-6.15%-12.73%-8.63%-6.98%1 Year Performance-20.37%-9.47%11.46%1.29% vTv Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTVTvTv Therapeutics2.4482 of 5 stars$19.70+4.7%$35.50+80.2%-18.4%$62.84M$1.02M-4.359Analyst ForecastShort Interest ↓CKPTCheckpoint Therapeutics1.6338 of 5 stars$3.99-0.5%$4.33+8.6%+141.9%$194.84M$41,000.00-2.1710YMABY-mAbs Therapeutics3.5162 of 5 stars$4.28-5.7%$18.30+327.6%-69.0%$193.53M$87.69M-7.93150Short Interest ↓Positive NewsNVCTNuvectis Pharma2.0821 of 5 stars$8.24-0.1%$15.67+90.1%+31.1%$192.75MN/A-7.108Positive NewsGap UpOCGNOcugen1.2958 of 5 stars$0.65-2.0%$6.33+876.2%-52.8%$189.46M$4.06M-3.6080LFCRLifecore Biomedical1.1386 of 5 stars$5.10-3.6%$8.00+56.9%-1.8%$188.83M$130.86M-9.11690News CoverageGap DownHigh Trading VolumeGOSSGossamer Bio3.6408 of 5 stars$0.82+2.6%$7.75+844.4%+2.4%$186.46M$114.70M-2.56180Analyst ForecastShort Interest ↑CRGXCARGO Therapeutics2.6164 of 5 stars$4.03+0.2%$15.00+272.2%-76.2%$185.59MN/A-0.95116High Trading VolumePLXProtalix BioTherapeutics2.6453 of 5 stars$2.34-2.1%$15.00+541.0%+127.0%$182.60M$53.40M-18.00200Gap DownHUMAHumacyte2.5518 of 5 stars$1.26-6.7%$13.71+988.4%-46.2%$182.50M$1.57M-0.94150Positive NewsGap UpZYBTZhengye BiotechnologyN/A$3.85-10.3%N/AN/A$181.59M$189.75M0.00278Gap Up Related Companies and Tools Related Companies CKPT Alternatives YMAB Alternatives NVCT Alternatives OCGN Alternatives LFCR Alternatives GOSS Alternatives CRGX Alternatives PLX Alternatives HUMA Alternatives ZYBT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTVT) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot...Stansberry Research | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding vTv Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share vTv Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VTVT Stock Free VTVT Stock Alerts